We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.41 | 0.57% | 248.25 | 249.73 | 247.59 | 248.45 | 1,787,707 | 01:00:00 |
From May 2021 to May 2024
By Dave Sebastian
Danaher Corp. said it expects adjusted full-year core revenue growth including Cytiva to be about 20%, up from its prior guidance of a growth in the high-teens percentage.
For the third quarter, the Washington, D.C.-based science and technology conglomerat Thursday said it expects adjusted core-revenue growth to be in the mid- to high-teens percentage range.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
July 22, 2021 06:30 ET (10:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
